RNAi Therapeutics Market is projected to grow at an annualized rate of ~45%, till 2030
Roots Analysis has done a detailedstudy on RNAiTherapeutics Market (2ndEdition), 2019-2030, covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.
To order this 350+ page report, which features 130+ figuresand 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Market Insights
§ Over 32,000 patentsrelated to RNAi therapeutics, indicating the heightened pace of research, havebeen filed / granted in the last several years
§ Presently, there isonly one approved drug and over 150 product candidates, which are beingevaluated for the treatment of a variety of disease indications, based on theRNAi principle
§ In order to achieve acompetitive edge, the drug developers are increasingly focusing on developingthe robust pipeline molecules across different therapeutic areas
§ Majority of the candidatetherapies are currently in the early stages of development and are based on thesiRNA approach; the innovation in this domain is being led by developersheadquartered in the US
§ Several trials evaluating various RNAi drug candidates against a widerange of therapeutic indications have been registered in the recent past
§ Investors, havingrealized the opportunity within this emerging segment of the pharmaceuticalindustry, have invested over USD 5 billion in capital across 65 instances, inthe period between 2014 and 2019
§ The increasing interest in this field is reflected in recent partnershipactivity; majority of deals inked were R&D and licensing agreements,featuring the participation of both international and indigenous stakeholders
§ In order to keeppatients and healthcare professionals informed and aware of the developments inthis field of medicine, companies are deploying diverse promotional strategiesfor their respective products
§ Prevalent trendsindicate that the market for RNAi therapeutics is poised to grow significantlyas multiple late stage molecules are commercialized in the near future, for thetreatment of different clinical conditions
For more information, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Table ofContents
1 PREFACE
1.1. Scope of theReport
1.2. Research Methodology
1.3. ChapterOutlines
2 EXECUTIVE SUMMARY
3 INTRODUCTION
3.1. ChapterOverview
3.2. HistoricalTrends
3.2.1. Discovery ofRNAi
3.2.2. RNAi TherapyDevelopment Efforts
3.3. Mechanism ofRNAi
3.3.1. Components ofRNAi
3.3.2. CellularMechanism
3.4. Types of RNAiMolecules
3.4.1. siRNA
3.4.2. miRNA
3.4.3. shRNA
3.5. Applicationsof RNAi
3.6. Advantagesand Disadvantages of RNAi
3.7. RegulatoryGuidelines
3.8. FuturePerspectives
4 COMPETITIVE LANDSCAPE
4.1. ChapterOverview
4.2. Marketed andDevelopment Pipeline
4.2.1. Analysis byType of RNAi Molecule
4.2.2. Analysis byPhase of Development
4.2.3. Analysis byType of Target Gene
4.2.4. Analysis byTherapeutic Area
4.2.5. Analysis byRoute of Administration
4.2.6. Analysis bySpecial Drug Designation
4.2.7. Key Players
4.3. DeveloperLandscape
4.3.1. Analysis byYear of Establishment
4.3.2. Analysis byCompany Size
4.3.3. Analysis byLocation of Headquarters
5 COMPANYCOMPETITIVENESS ANALYSIS
5.1. ChapterOverview
5.2. Methodology
5.3. Assumptionsand Key Parameters
5.4. CompetitivenessAnalysis
6 LATE STAGERNAi THERAPEUTICS
6.1. ChapterOverview
6.2. Onpattro®
6.2.1. Drug Overview
6.2.2. TechnologyOverview
6.2.3. CurrentDevelopment Status
6.2.4. Recent ClinicalTrial Results
6.3. ARO-AAT
6.3.1. Drug Overview
6.3.2. TechnologyOverview
6.3.3. CurrentDevelopment Status
6.3.4. RecentClinical Trial Results
6.4. Fitusiran
6.4.1. Drug Overview
6.4.2. TechnologyOverview
6.4.3. CurrentDevelopment Status
6.4.4. RecentClinical Trial Results
6.5. Givosiran
6.5.1. Drug Overview
6.5.2. TechnologyOverview
6.5.3. CurrentDevelopment Status
6.5.4. RecentClinical Trial Results
6.6. Inclisiran
6.6.1. Drug Overview
6.6.2. TechnologyOverview
6.6.3. CurrentDevelopment Status
6.6.4. RecentClinical Trial Results
6.7. Lumasiran
6.7.1. Drug Overview
6.7.2. TechnologyOverview
6.7.3. CurrentDevelopment Status
6.7.4. RecentClinical Trial Results
6.8. QPI-1002
6.8.1. Drug Overview
6.8.2. TechnologyOverview
6.8.3. CurrentDevelopment Status
6.8.4. RecentClinical Trial Results
6.9. SYL 1001
6.9.1. Drug Overview
6.9.2. TechnologyOverview
6.9.3. CurrentDevelopment Status
6.9.4. RecentClinical Trial Results
6.10. Vigil-EWS
6.10.1. Drug Overview
6.10.2. TechnologyOverview
6.10.3. CurrentDevelopment Status
6.10.4. RecentClinical Trial Results
6.11. Vutrisiran
6.11.1. Drug Overview
6.11.2. TechnologyOverview
6.11.3. CurrentDevelopment Status
6.11.4. RecentClinical Trial Results
7 TECHNOLOGY PLATFORMS ANDDELIVERY SYSTEMS
7.1. ChapterOverview
7.2. KeyComponents of RNAi Delivery Systems
7.2.1. RNAi Triggers
7.2.1.1. AsymmetricsiRNA (cp-siRNA)
7.2.1.2. DNA DirectedRNAi (ddRNAi)
7.2.1.3. DicerSubstrate siRNA (DsiRNA)
7.2.1.4. Naked siRNA
7.2.1.5. Self-DeliverableRNA (sd-RNA)
7.2.1.6. Self-DeliverablerxRNA (sd-rxRNA)
7.2.1.7. UnlockedNucleobase Analog (UNA) Containing siRNA (UsiRNA)
7.2.2. RNAi DeliveryTechnologies
7.2.2.1. CationicLiposomes
7.2.2.2. Lipid BasedNanoparticle
7.2.2.3. Polymer BasedNanoparticles
7.2.2.4. ConjugatedDelivery Systems
8 KEY THERAPEUTICINDICATIONS
8.1. ChapterOverview
8.2. OncologicalDisorders
8.2.1. Analysis by TargetIndication
8.2.2. Analysis byType of RNAi Molecule
8.3. InfectiousDiseases
8.3.1. Analysis byTarget Indication
8.3.2. Analysis byType of RNAi Molecule
8.4. GeneticDisorders
8.4.1. Analysis byTarget Indication
8.4.2. Analysis byType of RNAi Molecule
8.5. OphthalmicDiseases
8.5.1. Analysis byTarget Indication
8.5.2. Analysis byType of RNAi Molecule
8.6. RespiratoryDisorders
8.6.1. Analysis byTarget Indication
8.6.2. Analysis byType of RNAi Molecule
9 CLINICALTRIAL ANALYSIS
9.1. ChapterOverview
9.2. Scope andMethodology
9.3. RNAiTherapeutics: Clinical Trial Analysis
9.3.1. Analysis byTrial Registration Year
9.3.2. Analysis byTrial Phase
9.3.3. Analysis byRecruitment Status
9.3.4. Analysis byType of Sponsor / Collaborator
9.3.5. Analysis byType of RNAi Molecule
9.3.6. Analysis byTherapeutic Area
9.3.7. GeographicalAnalysis by Number of Clinical Trials
9.3.8. GeographicalAnalysis by Number of Clinical Trials, Trial Phase and Recruitment Status
9.3.9. GeographicalAnalysis by Number of Clinical Trials and Type of RNAi Molecule
9.3.10. GeographicalAnalysis by Number of Clinical Trials, Type of RNAi Molecule and Trial Phase
9.3.11. GeographicalAnalysis by Number of Clinical Trials and Therapeutic Area
9.3.12. GeographicalAnalysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
9.3.13. Analysis ofEnrolled Patient Population by Location of Trial
9.3.14. Analysis ofEnrolled Patient Population by Trial Phase and Recruitment Status
9.3.15. Analysis ofEnrolled Patient Population by Type of RNAi Molecule and Location of Trial
9.3.16. Analysis ofEnrolled Patient Population by Type of RNAi Molecule, Trial Phase and Locationof Trial
9.3.17. Analysis ofEnrolled Patient Population by Therapeutic Area and Location of Trial
9.3.18. Analysis ofEnrolled Patient Population by Therapeutic Area, Trial Phase and Location ofTrial
9.4. ConcludingRemarks
9.4.1. KeyTherapeutic Candidates
9.4.2. Key ClinicalTrials
10 PATENTANALYSIS
10.1. ChapterOverview
10.2. Scope andMethodology
10.3. RNAiTherapeutics: Patent Analysis
10.3.1. Analysis byPublication Year
10.3.2. Analysis byPatent Status
10.3.3. Analysis byCPC Code
10.3.4. Analysis byType of Organization
10.3.5. Analysis byGeographical Coverage
103.6. Emerging FocusArea
10.3.7. LeadingPlayers: Analysis by Number of Patents
10.4. RNAiTherapeutics: Patent Benchmarking Analysis
10.4.1. Analysis byKey Patent Characteristics
10.5. RNAiTherapeutics: Patent Valuation Analysis
11 RECENTPARTNERSHIPS
11.1. ChapterOverview
11.2. PartnershipModels
11.3. RNAiTherapeutics: Recent Partnerships
11.3.1. Analysis byYear of Partnership
11.3.2. Analysis byType of Partnership
11.3.3. Analysis byType of RNAi Molecule
11.3.4. Analysis byDuration of Partnership
11.3.5. Analysis byTherapeutic Area
11.3.6. Most ActivePlayers: Analysis by Number of Partnerships
11.3.7. RegionalAnalysis
11.3.7.1. Country-wiseDistribution
11.3.7.2. Intercontinentaland Intracontinental Deals
12 FUNDING ANDINVESTMENT ANALYSIS
12.1. ChapterOverview
12.2. Types ofFunding
12.3. RNAiTherapeutics: Funding and Investment Analysis
12.3.1. Analysis byCumulative Funding Instances, 2014-2019
12.3.2. Analysis byAmount Invested
12.3.3. Analysis byType of Funding
12.3.4. Analysis byYear and Type of Funding
12.3.5. Analysis byAmount Invested across Different Types of RNAi Molecules
12.3.6. RegionalAnalysis by Amount Invested
12.3.7. Most ActivePlayers
12.3.8. Key Investors
12.4. ConcludingRemarks
13 PROMOTIONALANALYSIS
13.1. ChapterOverview
13.2. Overview ofChannels used for Promotional Campaigns
13.3. Summary:Product Website Analysis
13.3.1. Summary: PatientSupport Services and Informative Downloads
13.4. PromotionalAnalysis: EXONDYS 51® (Eteplirsen)
13.4.1. Drug Overview
13.4.2. ProductWebsite Analysis
13.4.2.1. Message forHealthcare Professionals
13.4.2.2. Message forPatients
13.4.2.3. Patient AssistanceProgram (SareptAssist)
13.4.2.4. AdditionalInformation
13.4.3. OtherPromotional Strategies
13.5. PromotionalAnalysis: Defitelio®
13.5.1. Drug Overview
13.5.2. ProductWebsite Analysis
13.5.2.1. Message forHealthcare Professionals
13.5.2.2. Message forPatients
13.5.2.3. AdditionalInformation
13.5.3. OtherPromotional Strategies
13.6. PromotionalAnalysis: Onpattro®
13.6.1. Drug Overview
13.6.2. ProductWebsite Analysis
13.6.2.1. Message forHealthcare Professionals
13.6.2.2. Message forPatients
13.6.2.3. PatientAssistance Program – Alnylam Assist
13.6.2.4. AdditionalInformation
13.6.3. OtherPromotional Strategies
14 MARKET SIZING ANDOPPORTUNITY ANALYSIS
14.1. ChapterOverview
14.2. Scope andLimitations
14.3. KeyAssumptions and Forecast Methodology
14.4. Overall RNAiTherapeutics Market, 2019-2030
14.4.1. RNAiTherapeutics Market: Analysis by Type of RNAi Molecule
14.4.2. RNAiTherapeutics Market: Analysis by Therapeutic Area
14.4.3. RNAi TherapeuticsMarket: Analysis by Route of Administration
14.4.4. RNAiTherapeutics Market: Share of Leading Players
14.4.5. RNAiTherapeutics Market: Analysis by Geography
14.5. RNAiTherapeutics Market: Value Creation Analysis
14.6. RNAiTherapeutics Market: Product-wise Sales Forecasts
14.6.1. Onpattro®
14.6.1.1. Target PatientPopulation
14.6.1.2. Sales Forecast
14.6.1.3. Net PresentValue
14.6.1.4. Value CreationAnalysis
14.6.2. ARO-AAT
14.6.2.1. Target PatientPopulation
14.6.2.2. Sales Forecast
14.6.2.3. Net PresentValue
14.6.2.4. Value CreationAnalysis
14.6.3. Fitusiran
14.6.3.1. Target PatientPopulation
14.6.3.2. Sales Forecast
14.6.3.3. Net PresentValue
14.6.3.4. Value CreationAnalysis
14.6.4. Givosiran
14.6.4.1. Target PatientPopulation
14.6.4.2. Sales Forecast
14.6.4.3. Net PresentValue
14.6.4.4. Value CreationAnalysis
14.6.5. Inclisiran
14.6.5.1. Target PatientPopulation
14.6.5.2. Sales Forecast
14.6.5.3. Net PresentValue
14.6.5.4. Value CreationAnalysis
14.6.6. Lumasiran
14.6.6.1. Target PatientPopulation
14.6.6.2. Sales Forecast
14.6.6.3. Net PresentValue
14.6.6.4. Value CreationAnalysis
14.6.7. QPI-1002
14.6.7.1. Target PatientPopulation
14.6.7.2. Sales Forecast
14.6.7.3. Net Present Value
14.6.7.4. Value CreationAnalysis
14.6.8. SYL 1001
14.6.8.1. Target PatientPopulation
14.6.8.2. Sales Forecast
14.6.8.3. Net PresentValue
14.6.8.4. Value CreationAnalysis
14.6.9. Vigil-EWS
14.6.9.1. Target PatientPopulation
14.6.9.2. Sales Forecast
14.6.9.3. Net PresentValue
14.6.9.4. Value CreationAnalysis
14.6.10. Vutrisiran
14.6.10.1. Target PatientPopulation
14.6.10.2. Sales Forecast
14.6.10.3. Net PresentValue
14.6.10.4. Value CreationAnalysis
15 RNAi IN DIAGNOSTICS
15.1. ChapterOverview
15.2. KeyCharacteristics of a Biomarker
15.3. CirculatingmiRNA Biomarkers
15.4. miRNABiomarkers in Oncological Disorders
15.4.1. Importance ofEarly Cancer Detection
15.4.2. CancerScreening and Diagnosis
15.4.3. ConventionalCancer Diagnostics
15.4.4. Need forNon-Invasive Approaches
15.4.5. KeyIndications
15.4.5.1. Prostate Cancer
15.4.5.2. Breast Cancer
15.4.5.3. Lung Cancer
15.4.5.4. ColorectalCancer
15.4.5.5. Gastric Cancer
15.4.5.6. HematologicalCancer
15.5. miRNABiomarkers in Cardiovascular Diseases
15.5.1. KeyIndications
15.5.1.1. MyocardialInfarction (MI)
15.5.1.2. Coronary ArteryDisease (CAD)
15.6. miRNA BasedDiagnostic Tests
16 SERVICE PROVIDERS FOR RNAiTHERAPEUTICS
16.1. Chapter Overview
16.2. List ofService Providers
16.2.1. Analysis byType of Service Provider
16.2.2. Analysis byLocation of Service Provider
16.2.3. Analysis byType of RNAi Molecule
17 SWOT ANALYSIS
17.1. &n
